念珠菌血流感染临床特征及死亡相关危险因素分析

目的 探讨念珠菌血流感染的临床特点。方法 收集本院2017年1月—2021年12月确诊为念珠菌血流感染62例患者的临床资料,统计分析感染菌种分布、临床特征及死亡危险因素。结果 62例念珠菌血流感染患者共分离到65株真菌,主要分布在重症病房(33株)、泌尿外科(7株)和血液内科(6株)等科室;菌种以白念珠菌(29.2%)、光滑念珠菌(26.2%)、近平滑念珠菌(21.5%)、热带念珠菌(18.5%)为主,总体对氟康唑非敏感率38.5%。62例念珠菌血流感染患者中34例死亡,死亡率54.8%;单因素分析显示入住重症病房、机械通气、合并肺部感染、重度低蛋白血症和血培养报阳后48 h内未启动抗真菌治疗与死亡率相关(P<0.05);logistic回归分析提示重度低蛋白血症(OR=7.924,95%CI 1.851～34.599,P=0.006)、初次血培养报阳后48 h内未启动抗真菌治疗(OR=6.828,95%CI 1.377～33.852,P=0.019)是患者死亡独立危险因素。结论 念珠菌血流感染患者具有合并症多、死亡率高特点,感染以非白念珠菌为主,重度低蛋白血症是念珠菌血流感染患...     

118株口腔致病念珠菌病原学特征及药敏结果分析

目的调查分析临床致病口腔念珠菌菌种分布及对氟康唑、伊曲康唑、制霉菌素、5-氟胞嘧啶和酮康唑的药物敏感性,以提供临床用药依据。方法收集口腔真菌感染患者标本,常规涂片镜检、培养,对酵母样生长菌落用生物梅里埃公司API20AUX进行菌种鉴定。对其中的念珠菌进行药敏分析。结果共收集141例临床口腔真菌病标本,其中118株念珠菌中,白念珠菌87株（73.7%）,热带念珠菌15株（12.7%）,高里念珠菌6株（5.1%）,光滑念珠菌4株,其他念珠菌6株。口腔念珠菌对氟康唑、伊曲康唑、制霉菌素、5-氟胞嘧啶和酮康唑的耐药率分别为5.1%、1.7%、0%、3.4%、5.1%。结论解放军324医院口腔真菌感染主要为长期应用抗生素的老年患者。口腔念珠菌病仍以白念珠菌为主,对常用抗真菌药物呈不同程度的耐药,应进行真菌常规菌种鉴定及药敏试验。     

院内念珠菌血液感染的菌种分布及药敏分析

目的分析我院念珠菌血液感染的菌种比例、科室分布和体外药敏情况,为临床抗真菌药物的选择提供支持。方法回顾性分析无锡市第二人民医院在2013~2016年间血培养结果为念珠菌的病例,统计菌种分布及药敏结果等。结果血培养标本中念珠菌阳性病例共有56例,其中白念珠菌比例为57%(32/56),非白念珠菌占43%(24/56)。非白念珠菌菌株主要为近平滑念珠菌(20%,11/56)和光滑念珠菌(15.8%,9/56)。念珠菌感染病例主要分布在重症监护科(23.2%,13/56)和肾内科(17.9%,10/56)。白念珠菌与非白念珠菌对临床最常用的抗真菌药物氟康唑的敏感率差别最大,分别为93.8%和62.5%;56株念珠菌菌株对抗真菌药物两性霉素B和5-氟尿嘧啶的敏感性均为100%;55.6%的光滑念珠菌和72.7%的近平滑念珠菌对氟康唑敏感,所有克柔念珠菌株对氟康唑均耐药。结论本院近几年念珠菌血液感染的病原菌仍以白念珠菌为主,但非白念珠菌对一线抗真菌药物氟康唑的耐药性更高,临床上抗真菌的药物选择应充分考虑耐药问题。     

外阴阴道念珠菌病的病原检测及体外药敏试验

目的了解STD门诊患者外阴阴道念珠菌病的菌种分布及对常用抗真菌药物的敏感状况,为临床治疗提供参考。方法取STD门诊疑似念珠菌感染患者的阴道分泌物标本,用沙氏琼脂培养基分离纯化菌株,然后用ATB ID 32C酵母菌鉴定系统和ATB Fungus3药敏系统进行菌种鉴定与药物敏感试验。结果950份标本中检出306株念珠菌,占32.21%,其中白色念珠菌226株,阳性率为73.86%;光滑念珠菌37株,阳性率为12.09%;热带念珠菌24株,阳性率为7.84%;近平滑念珠菌13株,占4.25%。药敏结果显示：念珠菌对5-氟胞嘧啶（5-FC）;两性霉素B（AMB）,伏立康唑（VRC）耐药率〈6%;近平滑念珠菌对5种抗真菌药物均敏感;白色念珠菌对氟康唑（FCZ）、伊曲康唑（ICZ）耐药率依次：9.29%、11.06%,光滑念珠菌药耐药率依次为37.84%,67.57%,热带念珠菌药耐药率依次为8.33%、12.5%。结论STD门诊患者阴道念珠菌检出率明显高于普通妇科门诊患者,检出菌种仍以白色念珠菌为主,但光滑念珠菌和热带念珠菌生殖道感染有明显上升趋势;念珠菌对两性霉素B、5-氟胞嘧啶敏感性较高,对唑类药物有耐药菌株。因此,念珠菌鉴定和药敏监测是非常必要的,临床医生应根据药敏结果合理使用抗真菌药物。     

男性尿道炎和包皮龟头炎致病真菌的分布与药敏分析

目的了解男性念珠菌性尿道炎和包皮龟头炎的菌群分布及体外抗真菌药敏试验情况。方法菌株分离均来自复旦大学附属华山医院皮肤性病门诊临床症状轻重不一、真菌直接镜检阳性的61例患者。用科玛嘉念珠菌显色培养基及API 20C AUX鉴定系统进行菌种鉴定;采用CLSIM27-A2肉汤微量稀释法对61株临床分离念珠菌作了氟康唑、两性霉素B、氟胞嘧啶、伊曲康唑、伏立康唑、特比萘芬6种抗真菌药物敏感性测定。结果对培养阳性的61例菌株,通过科玛嘉念珠菌显色培养基及API 20C AUX鉴定系统作菌种鉴定,白念珠菌52例（85.2%）,近平滑念珠菌3例,光滑念珠菌2例,热带念珠菌2例,季也蒙念珠菌1例,克柔念珠菌1例。对52株白念珠菌的药敏试验显示氟康唑98.1%敏感,1.9%剂量依赖性敏感;氟胞嘧啶96.2%敏感,3.8%耐药;伊曲康唑44.2%敏感,40.5%剂量依赖性敏感,15.3%耐药;伏立康唑84.6%敏感,15.4%耐药;两性霉素B全部敏感;特比萘芬的MIC范围为1-64μg/ml,MIC50和MIC90皆为64μg/ml。结论在男性念珠菌性尿道炎和包皮龟头炎中,白念珠菌仍是第一位致病菌,体外药敏试验显示氟康唑、伏立康唑、氟胞嘧啶、两性霉素B对男性念珠菌性尿道炎均有较好的敏感性。     

外阴阴道念珠菌病致病菌种分布及流行特征分析

目的 阐明外阴阴道念珠菌病(VVC)致病菌种分布及流行特征。方法 收集VVC致病菌1 083株,分子鉴定(D1/D2)至菌种水平,回顾性收集VVC患者临床信息,分析不同致病菌种所致VVC临床特征。结果 白念珠菌为主要致病菌种(71.38%),非白念珠菌(NAC)占28.62%,其中,光滑念珠菌占19.02%。20～40岁、已婚、妊娠为VVC危险因素,孕期更易感染NAC。NAC致复发性VVC高于白念珠菌。结论 对VVC患者常规分泌物培养、菌种水平鉴定,结合体外药敏结果,对临床医生制定有效治疗方案具有重要参考价值。     

我国外阴阴道念珠菌病致病菌菌种分布及体外药敏研究现状

目的回顾性分析我国外阴阴道念珠菌病致病菌的菌种分布及体外药敏研究情况。方法检索分析万方、中国知网、维普、Pubmed等数据库15年来中国外阴阴道念珠菌病致病菌的菌种分布和体外药敏相关文献资料。结果共计检索筛选60篇文献,从现有数据来看,不同地区妇科患者中VVC的患病率为10%~40%,平均为20.3%;各地研究显示外阴阴道念珠菌病的主要病原体是白念珠菌,约占70%~90%,非白念珠菌以光滑念珠菌为主;非白念珠菌在复发性外阴阴道念珠菌病的病原体中所占比例更大。大多数研究显示氟康唑、制霉菌素、两性霉素B体外抗真菌活性较高,外阴阴道念珠菌病分离的念珠菌对氟康唑敏感率在70%~98%左右,对制霉菌素、两性霉素B的敏感率超过95%;过半的研究显示外阴阴道念珠菌病分离的念珠菌对伊曲康唑敏感性高;对5-FC、酮康唑的药敏结果各地差异较大。结论对VVC患者进行病原学鉴定和体外药敏检查十分重要,尤其是难治性VVC、复发性VVC患者,若发现病原菌为非白念珠菌,应根据体外药敏结果适当调整方案,可以选用非氟康唑类药物如AmB外用制剂、硼酸胶囊等;而对于大多数由白念珠菌引起的VVC,应用传统药物如氟康唑、制霉菌素、伊曲康唑等仍是较好的选择,酮康唑、5-FC等药物不建议作为常规选择。     

328株念珠菌菌种分布及耐药性分析

目的调查医院念珠菌病原分布及对常用抗真菌药物的耐药性,为临床抗真菌治疗提供参考依据。方法回顾性调查我院2008年6月～2009年6月从住院患者分离到的328株念珠菌的种类、分布及耐药性。结果念珠菌种类主要为白念珠菌（68.6%）、热带念珠菌（13.4%）和光滑念珠菌（7.9%）;念珠菌来源以下呼吸道为主（82.3%）,其次为泌尿道（5.2%）、血液（4.0%）和肠道（3.4%）等;白念珠菌对氟康唑、伏立康唑、氟胞嘧啶及两性霉素B耐药性较低（0.0%～7.1%）。结论医院念珠菌感染以白念珠菌为主,感染部位以下呼吸道多见,氟康唑、伏立康唑、氟胞嘧啶及两性霉素B对白念珠菌具有较好的抗菌活性。对于念珠菌属开展耐药性监测有重要的临床意义。     

连续5年无菌体液标本中分离真菌的鉴定及药敏分析

目的回顾性调查2002-2006年华西医院住院患者无菌体液标本真菌培养的情况,分析真菌菌种及其耐药特点,为临床诊断、治疗提供参考。方法标本接种沙堡弱培养基进行分离培养,采用科马嘉念珠菌显色培养基（CHRO-Ma-gar）和API-20CAUX鉴定系统结合形态学进行菌种鉴定,使用念珠菌药敏试条（ATB-Fungus 2）对2006年来自血液标本中的真菌进行药敏试验。结果2002-2006年间检出的阳性样本数依次为7株、22株、39株、32株及57株;血液来源73株,清洁中段尿来源59株,是主要样本来源;分离真菌以白念珠菌和热带念珠菌为主,占70%以上;2006年血培养中共分离出16株念珠菌,体外药敏情况详见文中。结论临床无菌体液标本中真菌的检出率有逐年上升的趋势;菌株以白念珠菌和热带念珠菌为主,同时近平滑念珠菌、克柔念珠菌、光滑念珠菌、马尔尼菲青霉菌等菌株也有出现;样本来源以血液、清洁中段尿为主;体外药敏总体耐药率低,但是逐渐出现了对氟康唑耐药的白念珠菌和热带念珠菌,应引起高度重视。     

热带念珠菌所致血流感染的临床及实验室分析CSCD

目的通过对热带念珠菌所致血流感染的临床特征及实验室检查结果进行分析,为临床预防及诊治提供一定的参考依据。方法收集2018年1月至2020年12月四川大学华西医院热带念珠菌血流感染患者的临床资料,回顾性统计分析患者的临床特征及实验室检查结果等。结果27例热带念珠菌血流感染患者均有基础疾病且伴有2种及以上危险因素,(1,3)-β-D-葡聚糖试验对辅助诊断热带念珠菌血流感染有很好的灵敏度,其余炎性指标如超敏C反应蛋白、降钙素原、白细胞介素-6均有不同程度增高;27株热带念珠菌对唑类抗真菌药物的敏感率依次为伊曲康唑(77.8%)、伏立康唑(48.2%)、氟康唑(48.2%)、泊沙康唑(37.0%),对两性霉素B、卡泊芬净、米卡芬净敏感率均是100%。结论热带念珠菌血流感染常发生于有基础疾病且合并多种危险因素的患者,针对临床高危患者,应及时完善实验室检查以明确诊断;热带念珠菌对唑类药物的敏感性较差,临床治疗时应重视药敏结果、合理用药、及时控制患者症状。     

Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994

BACKGROUND: Candida species are important bloodstream pathogens that are being isolated with increasing frequency. Despite the availability of effective antifungal therapy, the mortality rate associated with Candida infection remains high. With the objective of describing the epidemiology of candidemia, the Canadian Infectious Disease Society conducted a study of candidemia in Canada. METHODS: Fourteen medical centres across Canada identified all patients with candidemia from March 1992 to February 1994 through blood culture surveillance for Candida spp. Patient-related data for invasive fungal infection were compiled retrospectively by chart review using a standardized data-recording form developed for the Fungal Disease Registry of the Canadian Infectious Disease Society. Cases of Candidemia were studied in relation to underlying medical conditions, predisposing factors, concurrent infection, antimicrobial agents, antifungal treatment and deaths. RESULTS: In total, 415 cases of candidemia were identified, 48 (11.6%) in children and 367 (88.4%) in adults. The causative pathogens were C. albicans in 286 cases (68.9%), C. parapsilosis in 43 (10.4%), C. glabrata in 34 (8.2%), C. tropicalis in 27 (6.5%) and other Candida species in 18 (4.3%); polymicrobial candidemia occurred in 7 cases (1.7%). The overall mortality rate was 46%, and the rate of deaths clinically related to candidemia was 19%. However, only 13 (27%) of the children died. A univariate analysis indicated that significant risk factors for death were age greater than 60 years, therapy for concomitant bacterial infection, stay in an intensive care unit, concurrent malignant disease, cytotoxic chemotherapy and granulocytopenia, although only age and stay in an intensive care unit emerged as significant risk factors in the multivariate analysis. After adjustment for other predictors of death, only infection with C. parapsilosis was associated with a lower mortality rate than infection with C. albicans. Treatment was given in 352 (84.8%) of cases. Amphotericin B was the preferred agent in 244 cases (69.3% of those treated); fluconazole was used in 101 cases (28.7%) and ketoconazole in 5 cases (1.4%). INTERPRETATION: Candidemia in Canada is caused predominantly by C. albicans. The mortality rate associated with candidemia is high, but it varies with the species of Candida and is lower in children than in adults. Age greater than 60 years and stay in an intensive care unit were the most significant risk factors for overall mortality.     

Candidemia in a public hospital in Northeastern Brazil: Epidemiological features and risk factors in critically ill patients

BackgroundCandidemia is a life-threatening fungal infection characterized by the presence of Candida in the blood.AimsTo describe the clinical–epidemiological features and main risk factors among patients with candidemia admitted to Intensive Care Unit.MethodsA cross-sectional, retrospective and observational study was performed between January 2015 and July 2016. Laboratory reports and medical records from ICU patients admitted to a public hospital in northeastern Brazil were analyzed.ResultsThere were 1573 admissions and 67 of them were positive for candidemia. The majority of patients were male (53.3%) and remained at the hospital for more than seven days (86.6%). Non-C. albicans Candida infections (60%) were predominant. Broad-spectrum antibiotic therapy was prescribed in 98.4% of the cases. The most frequent underlying diseases were sepsis (73.3%), presence of solid tumors (15%), respiratory condition (60%), urinary tract disease (56.6%) and gastrointestinal tract diseases (23.3%). Surgeries were carried out on 43% of the patients, consisting of 23.3% abdominal surgeries, with a mortality rate of 92.8%. Risk factors were venous central access (93.3%), mechanical ventilation (81.6%), nasoenteral tube (83.3%), nasogastric tube (25%), indwelling bladder catheter (88.3%), diabetes mellitus (55%) and tracheostomy (36.6%). Statistical analysis correlated the use of indwelling bladder catheter with a higher mortality rate (r = 0.07412, p = 0.0353).ConclusionsThe current study reveals the high case fatality rates among critically ill patients suffering from candidemia admitted to ICU. Herein, we highlight the importance of identifying non-C. albicans Candida species and reinforce the idea of carrying out epidemiological surveillances and antifungal susceptibility tests.     

Invasive Mycosis in Medical Intensive Care Unit Patients with Severe Alcoholic Hepatitis

Background

Severe alcoholic hepatitis (AH) has a poor short-term prognosis often caused by infections. However, the incidence of invasive mycosis in patients with AH treated with corticosteroids and its impact still remains unknown.

Methods

Retrospective analyses of twelve medical ICU patients (out of 120 patients with liver cirrhosis) with histological proven AH.

Results

Twelve patients were diagnosed with histological proven AH during there stay at the ICU. All patients were treated with corticosteroids; three patients were treated with corticosteroids and pentoxifylline. Five patients had invasive aspergillosis (IA); three patients had candidemia; and two had fungal colonization with candida species. Only two patients had no evidence for fungals. IA was associated with death in all cases. Death occured in most cases shortly after diagnosis despite antifungal medication. Two patients with candidemia died; one patient died in the group with fungal colonization. Overall, the mortality rate was 100 % in patients with IA and 70 % in the group with candidemia.

Conclusions

Patients with severe AH have an increased susceptibility to invasive mycosis associated with high mortality. A high level of suspicion of invasive mycosis in AH patients and prophylactic strategies are needed in those patients.     

Nosocomial Candidemia in a tertiary care hospital in Saudi Arabia

Demographic information, risk factors, therapy, and outcome for all patients who had candidemia at King Fahad teaching hospital Al-khobar, between January 1995 and January 2000 were retrospectively reviewed. Thirty-two candidemic patients were identified. Candida parapsilosis was the most frequently isolated species (44%), followed by Candida tropicalis (25%), Candida albicans (19%), Candida krusei (6%), Candida glabrat a (3%), and Candida guilliermondi (3%). Risk factors included recent broad-spectrum antibiotics use (100%), ICU residency (71%), central venous catheters (66%), recent surgery (56%), total parenteral nutrition (43%), and immunosuppressive therapy (31%). Fluconazole was used before the onset of candidemia in only two patients. The overall mortality rate was 44%. Eight (25%) episodes of candidemia were not diagnosed and treated before the patient's demise. In view of the high mortality rate associated with hematogenous candidiasis, and lack of sensitive and specific laboratory tests necessary for the premortem diagnosis of infection, empirical antifungal therapy is recommended for high-risk patients. This revised version was published online in June 2006 with corrections to the Cover Date.     

临床分离161株念珠菌菌种鉴定及氟康唑药敏试验分析

目的调查临床分离的念珠菌种类及其对氟康唑的敏感性。方法采用科玛嘉念珠菌显色培养基和YBC平板对山东大学齐鲁医院细菌室分离到的161株念珠菌进行鉴定,并对分离出的白念珠菌分别采用NCCLS推荐的微量稀释法和ROSCO药敏纸片法对氟康唑进行药物敏感性试验。结果在161株念珠菌中白念珠菌为69．57％,热带念珠菌为19．88％,近平滑念珠菌为4．97％,克柔念珠菌为2．48％,光滑念珠菌为1．86％,其他念珠菌为1．24％。两种方法药敏结果显示：112株白念珠菌对氟康唑的敏感率分别为96．43％和97．32％,仅有2株耐药。结论白念珠菌仍然是我院分离率最高的念珠菌,其次是热带念珠菌和近平滑念珠菌。白念珠菌对氟康唑仍敏感,耐药菌株极少。     

Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy

Candida is an important cause of bloodstream infections (BSI), causing significant mortality and morbidity in health care settings. From January 2008 to December 2010 all consecutive patients who developed candidemia at San Martino University Hospital, Italy were enrolled in the study. A total of 348 episodes of candidaemia were identified during the study period (January 2008-December 2010), with an incidence of 1,73 episodes/1000 admissions. Globally, albicans and non-albicans species caused around 50% of the cases each. Non-albicans included Candida parapsilosis (28.4%), Candida glabrata (9.5%), Candida tropicalis (6.6%), and Candida krusei (2.6%). Out of 324 evaluable patients, 141 (43.5%) died within 30 days from the onset of candidemia. C. parapsilosis candidemia was associated with the lowest mortality rate (36.2%). In contrast, patients with C. krusei BSI had the highest mortality rate (55.5%) in this cohort. Regarding the crude mortality in the different units, patients in Internal Medicine wards had the highest mortality rate (54.1%), followed by patients in ICU and Hemato-Oncology wards (47.6%).This report shows that candidemia is a significant source of morbidity in Italy, with a substantial burden of disease, mortality, and likely high associated costs. Although our high rates of candidemia may be related to high rates of BSI in general in Italian public hospitals, reasons for these high rates are not clear and warrant further study. Determining factors associated with these high rates may lead to identifying measures that can help to prevent disease.     

Clinical and Therapeutic Aspects of Candidemia: A Five Year Single Centre Study

BackgroundCandida is an important cause of bloodstream infections (BSI) in nosocomial settings causing significant mortality and morbidity. This study was performed to evaluate contemporary epidemiology, species distribution, antifungal susceptibility and outcome of candida BSI in an Italian hospital.MethodsAll consecutive patients who developed candidemia at Santa Maria della Misericordia University Hospital (Italy) between January 2009 and June 2014 were enrolled in the study.ResultsA total of 204 episodes of candidemia were identified during the study period with an incidence of 0.79 episodes/1000 admissions. C. albicans was isolated in 60.3% of cases, followed by C. parapsilosis (16.7%), C. glabrata (11.8%) and C. tropicalis (6.4%). Of all Candida BSI, 124 (60.8 %) occurred in patients admitted to IMW, 31/204 (15.2 %) in ICUs, 33/204 (16.2%) in surgical units and 16/204 (7.8%) in Hematology/Oncology wards. Overall, 47% of patients died within 30 days from the onset of candidemia. C. parapsilosis and C. glabrata candidemia were associated with the lowest mortality rate (36%), while patients with C. tropicalis BSI had the highest mortality rate (58.3%). Lower mortality rates were detected in patients receiving therapy within 48 hours from the time of execution of the blood cultures (57,1% vs 38,9%, P <0.05). At multivariate analysis, steroids treatment (OR= 0.27, p=0.005) and CVC removal (OR=3.77, p=0.014) were independently associated with lower and higher survival probability, respectively. Candidemia in patients with peripherally inserted central catheters (PICC) showed to be associated with higher mortality in comparison with central venous catheters (CVC, Short catheters and Portacath) and no CVC use. For each point increase of APACHE III score, survival probability decreased of 2%. Caspofungin (OR=3.45, p=0.015) and Amphothericin B lipid formulation (OR=15.26, p=0.033) were independently associated with higher survival probability compared with no treatment.     

念珠菌血症时甘露聚糖抗原及其IgG抗体检测诊断价值的临床研究

目的评价念珠菌甘露聚糖抗原（M抗原）及甘露聚糖IgG抗体（M-IgG抗体）检测诊断念珠菌血症的价值。方法收集2013年5月～2014年1月我院住院患者及健康体检人群共107例,包括念珠菌血症组（念珠菌血培养阳性患者）13例、危险因素组（临床诊断侵袭性念珠菌病或接受化疗恶性疾病、留置深静脉置管等侵袭性念珠菌病感染高危患者）63例和对照组（健康体检人群）31例。通过ELISA方法检测甘露聚糖抗原及甘露聚糖IgG抗体,比较3组人群检测阳性情况及持续时间,计算两种方法的灵敏度、特异度、阴性预测值、阳性预测值、ROC曲线下面积及Kappa值。结果白念珠菌和光滑念珠菌为念珠菌血症的主要念珠菌病原,均为5例。念珠菌血症的7／14菌株（1例患者合并2种念珠菌感染）来自重症医学科,其次为感染内科（2／14株）。除1例死亡病例外,余12例患者进行了M抗原和M—IgG抗体监测。首次M抗原检测中,4例阳性,1例可疑阳性;首次M-IgG抗体检测中,11例阳性,1例可疑阳性。经抗真菌治疗,监测14d,M-IgG抗体持续阳性时间长于M抗原。甘露聚糖抗原在诊断念珠菌血症的敏感度41．7％,特异度98．8％,阴性预测值92．4％,阳性预测值100％。甘露聚糖IgG抗体在诊断念珠菌血症的敏感度91．7％,特异度52．8％,阴性预测值100％,阳性预测值27．5％。M抗原、M抗原并M—IgG抗体作为念珠菌血症时诊断实验的ROC曲线下面积均为0．708（95％CI：0．517—0．900）,两者的Kappa值分别为0．520和0．559。结论甘露聚糖抗原在诊断念珠菌血症时的特异度较高,甘露聚糖IgG抗体在诊断念珠菌血症的敏感性较高,两者的联合检测可以适当提高检测的敏感度及特异度,有助于念珠菌血症的诊断。     

The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards

The incidence of candidemia has increased over the past two decades, with an increased number of cases in Internal Medicine and a prevalence ranging from 24% to 57%. This single-center retrospective study was performed to evaluate the epidemiology and the risk factors associated with mortality of candidemia in patients admitted to Internal Medicine wards (IMWs) of the City of Health and Sciences, Molinette Hospital, Turin, from January 2004 to December 2012. For each patient, demographic, clinical and microbiological data were collected. A case of candidemia was defined as a patient with at least one blood culture positive for Candida spp. Amongst 670 episodes of candidemia, 274 (41%) episodes occurred in IMWs. The mortality was 39% and was associated at multivariate analysis with sepsis, cirrhosis and neurologic diseases, whilst removal of central venous catheter ≤48h was significantly associated with survival. In the 77 patients treated with early antifungal therapy the mortality was 29% and was not significantly different with caspofungin or fluconazole, whilst in patients with definitive therapy the mortality was significantly lower with echinocandins compared to fluconazole (11.7% Vs. 39%; p=0.0289), a finding confirmed by multivariate analysis. The mortality was significantly associated with sepsis, cirrhosis and neurologic diseases, whilst CVC removal ≤48h was associated with survival. In patients with early therapy, fluconazole or caspofungin were equally effective. However, echinocandins were significantly more effective as definitive treatment, a finding not explained by differences in treatment delays. Further studies are needed to understand the full potential of these different therapeutic strategies in IMWs.     

Increase in Candida parapsilosis Fungemia in Critical Care Units: A 6-Years Study

Objectives

We aimed to asses possible clinically significant differences between C. parapsilosis and other candida species candidemia receiving care in the intensive care unit (ICU) setting.

Methods

The study included 118 adult patients diagnosed as candidemia after admission to the ICU of a university hospital between January 2004 and December 2009. Data about demographic characteristics, underlying diseases, and risk factors for ICU-related candidemia were collected.

Results

During the study period, 118 patients with candidemia were identified among 2,853 patients admitted into the ICU. Candidemia was seen in 41.4 cases per 1,000 ICU admissions. The overall incidence of candidemia in ICU patients during the study period was 2.09 per 1,000 hospital admissions. Of the isolates, 18.6% were C. albicans and 81.4% were C. non-albicans. The species most frequently isolated was C. parapsilosis (66.1%, 78/118). The distribution of other Candida spp. was as follows: 15 had C. tropicalis (12.7%) and 3 had C. glabrata (2.5%). By Statistical analysis, when patients with candidemia who had C. parapsilosis were compared with other Candida spp., the following factors were found to be significantly associated with C. parapsilosis fungemia; intravascular catheters (p = 0.008), malignity (p = 0.049) and age (p = 0.039). Relationship was found between C. tropicalis and hematologic malignancies (p = 0.001).

Conclusions

When infections with a high mortality such as candidemia is suspected in critically ill patients, it is important to know local risk factors and epidemiological distributions of causative agents in selection of empirical and effective antifungal treatment.